Recent studies have revealed that DNA damage response inhibitors (DDRI), such as poly ADP-ribose polymerase inhibitors (PARPI), can enhance anti-tumor immunity by activating the cGAS-STING pathway [47]. Here, CGAS is linked to neoplasm.